KLOX Technologies (KLOX; Laval, QC, Canada) has reported the final results of its EUREKA clinical study that evaluated LumiHeal—a nonthermal and noninvasive treatment solution that uses hyper-pulsed fluorescence light (HPFL)—in the treatment of hard-to-heal, non-responsive, chronic wounds.
Related: KLOX BioPhotonic platform for dermatology set for expanded commercialization
Marco Romanelli, MD, Ph.D., associate professor of dermatology at the School of Medicine, University of Pisa, reported the final study results on the evaluation of real-life use of LumiHeal in chronic wounds management (venus leg ulcers [VLUs], diabetic foot ulcers [DFUs], and pressure ulcers). The results reported were on 99 patients who completed treatment in the EUREKA study.
The investigators' final analysis supports the strong efficacy profile of LumiHeal in promoting wound closure, along with wound bed preparation in hard-to-heal chronic wounds. These results indicate LumiHeal's ability, in a majority of cases, to transition hard-to-heal, non-responsive, chronic wounds into an acute wound setting.
Final results show that out of the 99 patients reported, 71% of them had a prognosis factor of poor healing at study entry; the average treatment duration for all types of wounds was 80.5 days; 47 of these hard-to heal, chronic wounds, closed completely during the study period; 96% of wounds that closed completely remained closed throughout the follow-up period; and 69.2% of VLUs and 68.8% of DFUs were ready for skin graft.
The results were reported at the European Wound Management Association conference (EWMA 2017), held May 3-5 in Amsterdam, Netherlands.
For more information, please visit www.kloxtechnologies.com.